Spain seeks to enhance financing for orphan drug access, signalling a push for better timelines and ...
Read moreThis article explores the new EU pharmaceutical package and criteria of high unmet medical need (HUM...
Read moreThis article explores the significant disparities between the US and Europe regarding orphan drugs a...
Read moreUnder ODAP, a protocol is drawn up “with criteria for starting, stopping and effect of a medicine....
Read moreThe paper examines potential reforms to current policies and practices related to orphan drug develo...
Read moreThe amendment includes a number of articles which aims to “streamline the negotiation of the price...
Read moreAccording to the pharmaceutical industry association, Farmaindustria, 40% of orphan drugs approved i...
Read moreThe Ministry of Health hhas published a report on the “evolution of funding and fixing of the pric...
Read more14 new orphan drugs were made available in the national health service (Sistema Nacional de Salud, S...
Read moreThe Court has annulled the inclusion of the orphan drug Onivyde (irinotecan) in the reference price ...
Read more